Differences in efficacy and safety among CAR-Ts anti-CD19/CD22, anti-CD19, and anti-CD22, in adult patients with relapse/refractory B-cell acute lymphoblastic leukemia: a meta-analysis and systematic review-Reference-Cited by-同舟云学术

Differences in efficacy and safety among CAR-Ts anti-CD19/CD22, anti-CD19, and anti-CD22, in adult patients with relapse/refractory B-cell acute lymphoblastic leukemia: a meta-analysis and systematic review

Published:2023-08-07 Issue:11 Volume:64 Page:1822-1831
ISSN:1042-8194
Container-title:Leukemia & Lymphoma
language:en
Short-container-title:Leukemia & Lymphoma

Author:

Becerril-Rico Jared¹²,Delgado-Montes Yerenia A.³,Ortiz-Sánchez Elizabeth¹

Affiliation:

1. Subdirección de investigación Básica, Instituto Nacional de Cancerología, Secretaría de Salud, Ciudad de México, México

2. Programa de posgrado en Ciencias Biológicas, Universidad Nacional Autónoma de México, Ciudad de México, México

3. Centro Médico Nacional La Raza, Instituto Mexicano del Seguro Social, Ciudad de México, México

Funder

Consejo Nacional de Humaninades, Ciencia y Tecnología

Publisher

Informa UK Limited

Subject

Cancer Research,Oncology,Hematology

Link

https://www.tandfonline.com/doi/pdf/10.1080/10428194.2023.2243357

Reference40 articles.

1. Recent advances in the treatment of acute lymphoblastic leukemia

2. Advances in adult acute lymphoblastic leukemia therapy

3. FLAG/FLAG-IDA regimen for children with relapsed/refractory acute leukemia in the era of targeted novel therapies

4. Survival after stem-cell transplant in pediatric and young-adult patients with relapsed and refractory B-cell acute lymphoblastic leukemia

5. Recent Advances in Managing Acute Lymphoblastic Leukemia

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Targeting Interleukin-13 Receptor α2 and EphA2 in Aggressive Breast Cancer Subtypes with Special References to Chimeric Antigen Receptor T-Cell Therapy;International Journal of Molecular Sciences;2024-03-28